Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Victorion-RIDES: Early In-hospital Inclisiran in Acute Coronary Syndromes (Japan)
jRCT2031250356Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Randomised, double-blind trial in hypercholesterolemia, acute coronary syndrome (ACS), myocardial infarction (MI) and 1 more comparing Inclisiran arm with Placebo arm (2 arms). Primary endpoint: Percent change in LDL-C. Started Oct 2025; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiaacute coronary syndrome (ACS)myocardial infarction (MI)Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on jRCT2031250356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250356.